

Clinical Trials - by cancer type

Key:

UIHC - University of Iowa, Holden Comprehensive Cancer Center, Iowa City

UIHC QC - UIHC Cancer Services Quad Cities, Bettendorf

HP - Oncology Associates at Hall Perrine Cancer Center/Mercy Cedar Rapids

PCI - Physicians Clinic of Iowa, Helen G. Nassif Cancer Center/UnityPoint Cedar Rapids

ICS - Iowa Cancer Specialists, Davenport

Genesis - Genesis Cancer Center, Davenport

MOneW - MercyOne Waterloo

WBCC - William Bliss Cancer Center, McFarland Clinic/Mary Greeley, Ames

Mission JS - Mission Cancer + Blood, John Stoddard, Des Moines

Mission MOne - Mission Cancer + Blood, MercyOne, Des Moines

McCreery - McCreery Cancer Center, Fairfield

JEN - June E. Nylen Cancer Center, Siouxland Hematology-Oncology Associates, Sioux City

Colon/Colorectal Cancer

1. **ATOMIC** - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ALLIANCE A021502, Clinical Trials ID: NCT02912559)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI/Alliance
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, ICS, Genesis, WBCC, Mission JS, JEN**
2. **PACES** - Adenoma and Second Primary Prevention Trial - Combination of eflornithine and sulindac (S0820, Clinical Trials ID: NCT01349881)
 - a. Phase III, Cancer Prevention in Colorectal Cancer Survivors
 - b. Sponsor - Southwest Oncology Group, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
 - i. Cooperative Group
 - c. **UIHC, HP, Mission MOne, JEN**
3. **COMMIT** - Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer (NRG-GI004/SWOG-S1610, Clinical Trials ID: NCT02997228)
 - a. Phase III, Metastatic
 - b. Sponsor - National Cancer Institute (NCI), NRG Oncology
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, WBCC, Mission JS, Mission MOne**
4. **BEACON CRC** - Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (ARRAY-818-302, Clinical Trials ID: NCT02928224)
 - a. Phase III, Metastatic
 - b. Sponsor - Array BioPharma, Merck KGaA, Darmstadt, Germany, Pierre Fabre Medicament, Ono Pharmaceutical Co. Ltd
 - i. Industry
 - c. **UIHC**

5. **NRG-GI002** - Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (NRG-GI002, Clinical Trials ID: NCT02921256)
 - a. Phase II, Neoadjuvant
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **UIHC, HP, ICS, Genesis, WBCC, Mission JS**
6. **NRG-GI005** - Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (NRG GI005, Clinical Trials ID: NCT04068103)
 - a. Phase II/III, Adjuvant
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **PCI, WBCC**
7. **SOLARIS** - Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (A021703, Clinical Trials ID: NCT04094688)
 - a. Phase III, Metastatic
 - b. Sponsor - NCI, Alliance
 - i. Cooperative Group
 - c. **HP, WBCC**
8. **CETIRI** - A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 amplification (S1614, Clinical Trials ID: NCT03365882)
 - a. Phase II, Advanced/Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **Mission JS**
9. **REVERCE II** - A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (Clinical Trials ID: NCT04117945)
 - a. Phase II, Metastatic
 - b. Sponsor - Academic and Community Cancer Research United, NCI
 - i. Federally funded
 - c. **JEN**

Breast Cancer

1. **BTCRC-BRE18-337** - Gedatolisib plus Talazoparib for Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancer (Clinical Trials ID: NCT03911973)
 - a. Phase II, Metastatic
 - b. Sponsor - Dr. Kari Wisinski, Pfizer
 - i. Investigator-initiated, industry
 - c. **UIHC**
2. **COMET** - COMPARISON of OPERATIVE to MONITORING AND ENDOCRINE THERAPY TRIAL FOR LOW RISK DCIS (AFT-25, Clinical Trials ID: NCT02926911)
 - a. Phase III, Surgical

- b. Sponsor - Alliance Foundation Trials, LLC, Patient-Centered Outcomes Research Institute, Duke University, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center, New York University, Washington University School of Medicine
 - i. Cooperative Group
 - c. **UIHC, Mission JS**
 - 3. **NRG-CC004** - Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gyn Cancer (NRG-CC004, Clinical Trials ID: NCT03180294)
 - a. Phase II, Supportive care
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **PCI, Mission JS, Mission MOne, JEN**
 - 4. **NRG-BR002** - A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (NRG-BR002, Clinical Trials ID: NCT02364557)
 - a. Phase II/III, Radiotherapy
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **Mission JS, Mission MOne**
 - 5. **NRG-BR003** - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003, Clinical Trials ID: NCT02954874)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI, NRG
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, ICS, Genesis, WBCC, Mission JS, Mission MOne, McCreery, JEN**
 - 6. **NRG-BR004** - Testing the drug atezolizumab or placebo with usual therapy in first-line HER2-positive metastatic breast cancer (NRG-BR004, Clinical Trials ID: NCT02488967)
 - a. Phase III, Metastatic
 - b. Sponsor - NCI, NRG
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, WBCC, Mission JS**
 - 7. **NRG-BR005** - Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery (NRG-BR005, Clinical Trials ID: NCT03188393)
 - a. Phase III, Surgical
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **UIHC**
 - 8. **S1418/BR006** - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (S1418/BR006, Clinical Trials ID: NCT02954874)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, PCI, ICS, Genesis, WBCC, Mission JS, Mission MOne, McCreery**
 - 9. **NSABP FB-12** - An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and

Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction- FACT 1 (NSABP FB-12, Clinical Trials ID: NCT03412643)

- a. Phase II, Neoadjuvant
- b. Sponsor - NSABP Foundation
 - i. Cooperative Group
- c. **UIHC**

10. **NSABP B-51** - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51, Clinical Trials ID: NCT02364557)

- a. Phase III, Radiotherapy
- b. Sponsor - NSABP Foundation, NCI, RTOG
 - i. Cooperative Group
- c. **Mission JS, Mission MOne**

11. **BWEL** - Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (ALLIANCE A011401, Clinical Trials ID: NCT02750826)

- a. Phase III, Adjuvant
- b. Sponsor - Alliance, NCI Division of Cancer Control, NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Canadian Cancer Trials Group
 - i. Cooperative Group
- c. **UIHC, UIHC QC, HP, ICS, Genesis, WBCC, Mission JS, Mission MOne, JEN**

12. **A011202** - Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy (ALLIANCE A011202, Clinical Trials ID: NCT01901094)

- a. Phase III, Surgical
- b. Sponsor - Alliance, National Cancer Institute (NCI), Canadian Cancer Trials Group
 - i. Cooperative Group
- c. **UIHC, HP, PCI, Mission JS, Mission MOne**

13. **A221702 ARM**: Axillary Reverse Mapping – A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping (A221702, Clinical Trials ID: NCT03927027)

- a. Phase III, Surgical
- b. Sponsor - Alliance, NCI
 - i. Cooperative Group
- c. **Mission JS**

14. **A011502** - Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy (A011502, Clinical Trials ID: NCT02927249)

- a. Phase III, Adjuvant
- b. Sponsor - Alliance, NCI
 - i. Cooperative Group
- c. **ICS, Genesis, WBCC, Mission JS, Mission MOne, McCreery, JEN**

15. **A221505** - Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (ALLIANCE A221505, Clinical Trials ID: NCT03414970)

- a. Phase III, Radiotherapy
- b. Alliance, NCI, Canadian Cancer Trials Group

- i. Cooperative Group
 - c. **WBCC, Mission JS, Mission MOne**
- 16. **A171601** - A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients 70 years and older with ER-pos, HER2-negative metastatic breast cancer (**A171601, Clinical Trials ID: NCT03633331**)
 - a. Phase II, Metastatic (QOL study)
 - b. Sponsor - NCI, Alliance
 - i. Cooperative Group
 - c. **PCI, Mission JS**
- 17. **EA1131** - Platinum Based Chemotherapy Vs Capecitabine in Patients with Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (ECOG-ACRIN EA1131, Clinical Trials ID: NCT02445391)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI, ECOG-ACRIN
 - i. Cooperative Group
 - c. **HP, ICS, Genesis, WBCC, Mission JS, Mission MOne, McCreery, JEN**
- 18. **EA1181** - CompassHER2-pCR: Pre-op THP and Post-opHP in Patients who Achieve a Pathologic Complete Response (EA1181, Clinical Trials ID: NCT04266249)
 - a. Phase ?, Neoadjuvant/Adjuvant
 - b. Sponsor - ECOG/ACRIN, NCI
 - i. Cooperative Group
 - c. **WBCC**
- 19. **IOeRT** - Hypofractionated Whole-Breast Irradiation preceded by Intraoperative Radiotherapy w/Electrons as anticipated Boost - HIOC (IOeRT, Clinical Trials ID:?)
 - a. Single group assignment, Adjuvant Radiation
 - b. Sponsor - ?
 - c. **PCI**
- 20. **WF97116** - A Phase III Placebo Controlled Trial of Donepezil in Chemo Exposed Breast Cancer Survivors with Cognitive Impairment (WF97116, Clinical Trials ID: NCT02822573)
 - a. Phase III, Supportive care
 - b. Sponsor - Wake Forest, NCI
 - i. Cooperative Group
 - c. **PCI, Mission JS, Mission MOne**
- 21. **S1416** - Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer (S1416, Clinical Trials ID: NCT02595905)
 - a. Phase II, Metastatic
 - b. NCI
 - i. Cooperative Group
 - c. **Mission JS**
- 22. **S1703** - Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER2 Negative Breast Cancer (S1703, Clinical Trials ID: NCT03723928)
 - a. Phase III, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **WBCC, Mission JS, Mission MOne**

23. **S1706** - Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer (S1706, Clinical Trials ID: NCT03598257)
 - a. Phase II, Adjuvant
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **WBCC, Mission JS**
24. **S1501** - Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer (S1501, NCT03418961)
 - a. Phase III, Supportive Care
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **Mission JS, Mission MOne**
25. **MA.39, Tailor RT** - A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (MA.39, Clinical Trials ID: NCT03488693)
 - a. Phase III, Radiotherapy
 - b. Sponsor - Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, Southwest Oncology Group
 - i. Cooperative Group
 - c. **Mission JS, Mission MOne**
26. **IMpassion030** - A Phase III, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer (Clinical Trials ID: NCT03498716)
 - a. Phase III, Adjuvant
 - b. Sponsor - Hoffman LaRoche, Breast International Group, Alliance Foundation Trials (AFT), Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU), Frontier Science and Technology Research Foundation Inc (FS)
 - i. Industry/Cooperative Group
 - c. **Mission JS**
27. **NCT03642990** - Nicotinamide Riboside in Chemo-induced Peripheral Neuropathy (Clinical Trials ID: NCT03642990)
 - a. Phase II, Supportive
 - b. Sponsor - Donna Hammond, NCI, ChromaDex Inc
 - i. Investigator-initiated
 - c. **UIHC**

Lung Cancer

1. **ALCHEMIST** - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALLIANCE A151216, Clinical Trials ID: NCT02194738)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, PCI, ICS, Genesis, WBCC, Mission JS, Mission MOne, McCreery**
2. **NCT02769832** - Abraxane + Gemcitabine for Small Cell Lung Cancer (Clinical Trials ID: NCT02769832)
 - a. Phase II, Metastatic
 - b. Sponsor - Dr. Muhammad Furqan, Celgene
 - i. Investigator-initiated, Industry

- c. **UIHC, UIHC QC**
- 3. **NCT03743064** - A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (**Clinical Trials ID: NCT03743064**)
 - a. Phase III, Supportive Care
 - b. Sponsor - Helsinn Healthcare SA
 - i. Industry
- c. **JEN**
- 4. **NCT03228537** - Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients with Stage I-III Pleural Malignant Mesothelioma (Clinical Trials ID: NCT03228537)
 - a. Phase 1, Radiation
 - b. Sponsor - NCI
 - i. Federally funded
- c. **Mission MOne**
- 5. **BTCRC-LUN15-017** - Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium (BTCRC-LUN15-017, Clinical Trials ID: NCT03003468)
 - a. Phase Ib/II, Metastatic
 - b. Sponsor - Dr. Lawrence Feldman, Merck Sharp & Dohme Corp, Biothera
 - i. Investigator-initiated, Industry
- c. **UIHC**
- 6. **BTCRC-LUN17-139** - A phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer: Big Ten Cancer Research Consortium (BTCRC-LUN17-139, Clinical Trials ID: NCT03713944)
 - a. Phase II, Metastatic
 - b. Sponsor - Big 10 Cancer Research Consortium, Genentech
 - i. Investigator-initiated, Industry
- c. **UIHC**
- 7. **BTCRC-LUN15-029** - A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium (BTCRC-LUN15-029, Clinical Trials ID: NCT03083808)
 - a. Phase II, Metastatic/Advanced
 - b. Sponsor - Dr. Greg Durm, Merck Sharp & Dohme Corp, Big Ten Cancer Research Consortium
 - i. Investigator-initiated, industry
- c. **UIHC**
- 8. **EA5163** - A Randomized Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non-Small cell Lung Cancer (NSCLC) with Immunobiomarker - SIGNature-Diven Analysis (EA5163, Clinical Trials ID: NCT03793179)
 - a. Phase III, Metastatic/Advanced
 - b. Sponsor - NCI
 - i. Cooperative Group/Federally funded
- c. **HP, WBCC, Mission JS**

9. **E5142** - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers - an ALCHEMIST Treatment Trial (EA5142, Clinical Trials ID: NCT02595944)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI
 - i. Cooperative Group
 - c. **Mission JS**
10. **E5162** - Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR (EA5162, Clinical Trials ID: NCT03191149)
 - a. Phase II, Metastatic/Advanced
 - b. Sponsor - NCI
 - i. Cooperative Group
 - c. **Mission JS**
11. **E4512** - Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations - An ALCHEMIST Treatment Trial (ECOG-ACRIN E4512, Clinical Trials ID: NCT02201992)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI, ECOG/ACRIN
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, PCI, ICS, Genesis, WBCC, Mission JS, McCreery, JEN**
12. **A081105** - Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery - An ALCHEMIST Treatment Trial (ALLIANCE A081105, Clinical Trials ID: NCT02193282)
 - a. Phase III, Adjuvant
 - b. Sponsor - NCI, Alliance
 - i. Cooperative Group
 - c. **UIHC, UIHC QC, HP, PCI, ICS, Genesis, WBCC, Mission JS, McCreery, JEN**
13. **A221504** - A Randomized, Double-Blind, Placebo-Controlled Pilot of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (A221504, Clinical Trials ID: NCT03087708)
 - a. Phase ? Randomized Pilot Study, Supportive Care/Metastatic and Advanced
 - b. Sponsor - Alliance, NCI
 - i. Cooperative Group
 - c. **WBCC, Mission JS, Mission MOne, JEN**
14. **Cypress 1** - Study of Pegilodexakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Clinical Trials ID: NCT03382899)
 - a. Phase II, Metastatic
 - b. Sponsor - Eli Lilly
 - i. Industry
 - c. **UIHC**
15. **PACIFIC-4** - Phase III Randomized, Placebo controlled Study of Durvalumab for Stage I/II Non-Small Cell Lung Cancer (SN) - PACIFIC-4 (Clinical Trials ID: NCT03833154)
 - a. Phase III, Adjuvant
 - b. Sponsor - AstraZeneca
 - i. Industry
 - c. **UIHC**

16. **S1400** - Biomarker-Targeted Second Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer Lung-MAP trial S1400, Clinical Trials ID: NCT02154490)
 - a. Phase II/III, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **Mission MOne**
17. **S1400F** - Durvalumab and Tremelimumab in Treating Patients with Recurrent Stage IV Lung Cancer - LungMAP Sub-Study (S1400F, Clinical Trials ID: NCT03373760)
 - a. Phase II, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **ICS, Genesis**
18. **S1619** - Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma (S1619, Clinical Trial ID: NCT03228537)
 - a. Phase I pilot, neoadjuvant chemo/radiation, adjuvant/maintenance
 - b. Sponsor - NCI
 - i. Cooperative group/Federally funded
 - c. **WBCC**
19. **S1800A** - A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent NSCLC -Lung-MAP Non-Matched Sub-Study (S1800A, Clinical Trials ID: NCT03971474)
 - a. Phase II, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **HP, ICS, Genesis, WBCC, JEN**
20. **S1900A** - A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA ½ Mutation Stage IV or Recurrent NSCLC - LungMAP Sub-Study (S1900A, Clinical Trials ID: NCT03845296)
 - a. Phase II, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **HP, ICS, Genesis, WBCC, JEN**
21. **1900B** - A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer - Lung-MAP Sub-Study (S1900B, Clinical Trials ID: NCT04268550)
 - a. Phase II, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **WBCC,**
22. **1900C** - Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small cell Lung Cancer with STK11 Gene Mutation - LungMAP Sub-Study (S1900C, Clinical Trials ID: NCT04173507)
 - a. Phase II, Metastatic
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **ICS, Genesis**

23. **NRG-LU002** - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial (NRG-LU002, Clinical Trials ID: NCT03137771)
 - a. Phase II/III, Metastatic
 - b. Sponsor - NRG, NCI
 - i. Cooperative Group
 - c. **Mission JS**
24. **NRG-LU003** - Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NRG-LU003, Clinical Trials ID: NCT03737994)
 - a. Phase II, Metastatic
 - b. Sponsor - NCI, NRG
 - i. Cooperative Group
 - c. **WBCC**
25. **NRG-LU005** - Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer (NRG-LU005, Clinical Trials ID: NCT03811002)
 - a. Phase II/III, Limited Stage Small Cell
 - b. Sponsor - NCI, NRG
 - i. Cooperative Group
 - c. **WBCC**
26. **NRG-CC003** - Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (NRG-CC003, Clinical Trials: NCT02635009)
 - a. Phase II/III, Radiotherapy
 - b. Sponsor - NRG, NCI, RTOG
 - i. Cooperative Group
 - c. **Mission JS**
27. **CALGB-30610** - Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide (CALGB-30610, Clinical Trials ID: NCT00632853)
 - a. Phase III, Radiation
 - b. Sponsor - Alliance, NCI
 - i. Cooperative Group
 - c. **Mission MOne**
28. **KEYNOTE-789** - Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789, Clinical Trials ID: NCT03515837)
 - a. Phase III, Metastatic
 - b. Sponsor - Merck
 - i. Industry
 - c. **JEN**

Prostate Cancer

1. **TALAPRO-2** - Phase 3 Talazoparib with Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (Clinical Trials ID: NCT03395197)
 - a. Phase III, Metastatic
 - b. Sponsor - Pfizer
 - i. Industry
 - c. **UIHC**

2. **CHAARTED2** - Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial (ECOG-ACRIN EA8153, Clinical Trials ID: NCT03419234)
 - a. Phase II, Metastatic
 - b. Sponsor - NCI, ECOG/ACRIN
 - i. Cooperative Group
 - c. **UIHC, WBCC, Mission JS**
3. **VISION** - Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (Clinical Trials ID: NCT03511664)
 - a. Phase II, Metastatic
 - b. Sponsor - Endocyte
 - i. Industry
 - c. **UIHC**
4. **NCT00859781** - A Randomized, Phase 2 Trial of 177Lu-J591 + Ketoconazole for High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy (Clinical Trials ID: NCT00859781)
 - a. Phase II, Biochemically relapsed
 - b. Sponsor - Weill Medical College of Cornell University, United States Department of Defense
 - i. Federally funded
 - c. **UIHC**
5. **NRG-GU002** - Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel (NRG-GU002, Clinical Trials ID: NCT03070886)
 - a. Phase II-III, Adjuvant
 - b. Sponsor - NCI, NRG
 - i. Cooperative Group
 - c. **HP, WBCC**
6. **S1802** - Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer (S1802, Clinical Trials ID: NCT03678025)
 - a. Phase III, Metastatic/Surgical
 - b. Sponsor - SWOG, NCI
 - i. Cooperative Group
 - c. **WBCC**